top of page


The Cost and Complexities of Treating Cancer are Astronomical—and on the Rise

Now, some US oncologists are collaborating with genomic labs and payers through an evidence-based technology to reduce treatment costs and improve patient outcomes.


Precision medicine is changing the way cancer is tested and treated in the US, but a lack of standardization and barriers to collaboration between oncologists, payers and genomic testing labs has been slowing its use.

In fact, the gap between how oncologists and payers make oncology care decisions has never been greater, and it is impeding the application of life-saving therapies.


The solution? The battle royale between payers and oncologists must end to ensure cancer patients are getting the most appropriate precision testing and therapies at the right stage of their treatment journeys. But how?



Debra Patt, M.D., Ph.D., MBA

Health economics and health services research oncologist and breast cancer expert at Texas Oncology

  • What is causing the “battle royale” between oncologists and payers

  • Why we need a modern prior authorization process

  • How to close the gap and bring precision medicine to more patients


Russ Ingersoll, Ph.D.

Chief Product Officer and pharmacology and toxicology expert at Trapelo Health

Cancer is among the top five most expensive diseases that account for over 80% of all health care spending and those costs are expected to increase to $246 billion by 2030.

Learn More

Sign up and receive more insights on the latest advances, opinions, and news in precision medicine decision support.

See Trapelo in a brief live demo

How can we resolve the complexities of using precision medicine for cancer care?

Trapelo knows.

bottom of page